WWW.DISSERTATION.XLIBX.INFO
FREE ELECTRONIC LIBRARY - Dissertations, online materials
 
<< HOME
CONTACTS



Pages:   || 2 | 3 | 4 | 5 |   ...   | 10 |

«Department of Communicable Disease Surveillance and Response WHO Global Influenza Programme WHO Guidelines on the Use of Vaccines and Antivirals ...»

-- [ Page 1 ] --

WHO Guidelines on the Use

of Vaccines and Antivirals

during Influenza Pandemics

Department of Communicable Disease

Surveillance and Response

WHO Global Influenza Programme

WHO Guidelines on the Use

of Vaccines and Antivirals

during Influenza Pandemics

World Health Organization

Department of Communicable Disease

Surveillance and Response

© World Health Organization 2004

All rights reserved.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.

Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.

WHO/CDS/CSR/RMD/2004.8 WHO Guidelines on the Use of Vaccines and Antivirals during Influenza Pandemics

CONTENTS

1. Introduction

2. Background

3. Guidelines for the use of vaccines and antivirals

3.1 Establishing goals and priorities

3.2 Guidelines on vaccine use during a pandemic

3.2.1 General considerations

3.2.2 Establishing priority groups

Essential service providers, including health care workers

Groups at high risk of death and severe complications requiring hospitalization

Persons without risk factors for complications

3.3 Guidelines for antiviral use during a pandemic

3.3.1 General considerations

3.3.2 Options for antiviral use

3.3.3 Establishing priority groups

Essential service providers, including health care workers (prophylaxis or treatment).................. 8 Groups at high risk of death and severe complications requiring hospitalization (prophylaxis or treatment)

Persons without known risk factors for complications from influenza (treatment)

4. Recommendations

4.1 Recommendations for establishing goals

4.2 Vaccines

4.2.1 Recommendations for national authorities and vaccine manufacturers

4.2.2 Recommendations for international collaboration

4.2.3 Recommendations for research

4.3 Antivirals

4.3.1 Recommendations for national authorities

4.3.2 Recommendations for research

4.4 Surveillance

Annex 1 - Pandemic Influenza Annex 2 - List of participants Annex 3 - Global Agenda on Influenza Surveillance and Control Annex 4 - Considerations for the Use of Vaccines during an Influenza pandemic Annex 5 - Considerations for the Use of Antivirals during an Influenza pandemic –1– WHO Guidelines on the Use of Vaccines and Antivirals during Influenza Pandemics WHO/CDS/CSR/RMD/2004.8

1. Introduction Influenza pandemics are sudden and unpredictable yet inevitable events. They have caused several global health emergencies during the last century. The first and most severe of these is estimated to have resulted in more than 40-50 million deaths worldwide1. Experts anticipate that the next pandemic, whenever it happens, will be associated with a high death toll and a high degree of illness requiring hospitalization, thus producing a considerable strain on health care resources. Pandemics are global by their very nature, and few countries are likely to be spared. In developing countries, where health care resources are already strained and the general population is frequently weakened by poor health and nutritional status, the impact is likely to be greatest (Annex 1).

Conditions surrounding the 1997 Hong Kong outbreak of “chicken influenza” highlight the need for advance planning to ensure an adequate response to a health emergency that is certain to be unpredictable, complex, rapidly evolving and accompanied by considerable public alarm. Once a pandemic begins it will be too late to accomplish the many key activities required to minimize the impact. Therefore, planning and implementation of preparatory activities must start well in advance.

Planning for pandemics will also enhance the capacity to respond to other large-scale health emergencies, including bioterrorist threats, that require mass access to prophylactic and therapeutic interventions and strong national plans which include a risk communication component to help calm public fears. The impact of pandemic influenza is likely to be far greater, by orders of magnitude, than most bioterrorism scenarios. Unlike most other health emergencies, pandemics occur in several waves and last one to two years. Response efforts will, therefore, need to be sustained for a prolonged period.

In addition, preparation for an influenza pandemic will enhance the response to influenza epidemics, which occur each year and are thought to kill every year from 500 000 to 1 million people worldwide.





Investment in pandemic preparedness thus has direct and immediate utility as a measure for reducing the impact of a certain and recurring event.

Influenza vaccines and antiviral drugs for influenza are essential components of a comprehensive pandemic response, which also includes planning for antibiotic supplies and other health care resources. However, the current reality is that most countries have no or very limited supplies. Such a situation would force national authorities to make difficult decisions concerning which citizens should receive first call on limited vaccines and drugs.

This document provides guidance to health policy-makers and national authorities on planning principles and options for the prioritization of vaccine and antiviral use during an influenza pandemic.

It includes recommendations on actions that can improve future supply for the many countries that currently have no national vaccine or antiviral production.

The document was drafted during a WHO Consultation on Guidelines for the Use of Vaccines and Antivirals during Influenza Pandemics, held from 2-4 October 2002 in Geneva, Switzerland.

Participants are listed in Annex 2. The document represents a contribution of the WHO Global Influenza Programme to the implementation of the Global Agenda on Influenza, reproduced in Annex 3.

–  –  –

2. Background Influenza vaccines have been available for over 60 years. Extensive experience during this long period has demonstrated their safety and efficacy. In populations at risk of severe complications, vaccination is known to reduce hospital admissions and deaths. Vaccination is thus the cornerstone of influenza prevention. As influenza viruses are constantly evolving, vaccine is produced each year with a composition based on the most relevant strains of virus identified through a global surveillance system.

Stockpiling of vaccine in preparation for a pandemic is not an option, as vaccine composition depends on the responsible virus and must await its appearance and identification at the start of the pandemic.

Vaccine will thus be in limited supply during the first part of the pandemic, and may not be available at all in some parts of the world.

The influenza antivirals currently in use will likely be effective in the prophylaxis and therapy of illness caused by a new pandemic virus. However, supplies would quickly be exhausted in the first part of the pandemic, when vaccine is not yet available and demand for an alternative control tool would be greatest. Advance stockpiling of the drugs for special purposes or special populations is one solution.

As the drugs are relatively stable, stockpiling is feasible; however, for most countries, cost will be an issue. Also, differences do exist between the M2 inhibitors, such as amantadine, and the neuraminidases, such as oseltamivir, requiring identification of their specific roles in a pandemic.

Because of these factors, countries will need to consider the potential for complementary use of vaccines and antivirals in planning for various phases of a pandemic. Vaccine will remain the primary means of influenza prevention once available, though antivirals will have a role for use in special situations.

Countries will be able to address pandemic requirements only if they plan for supplies of vaccines and antivirals now. Although vaccines and antivirals are a key part of a pandemic response strategy, the current market-based system has limited or no surge capacity to respond to sudden increases in demand. Manufacturers require regular estimates of demand on which to base production plans.

However, there are currently no estimates on the global use and demand for influenza vaccine and antivirals. In addition, vaccine distribution systems are often fragmented and may not be readily adapted to respond to a single overall national plan. Issues of liability also require resolution in advance of the next pandemic.

3. Guidelines for the use of vaccines and antivirals The response to the next influenza pandemic will need to address an inevitable shortage of vaccines and antivirals. Thus, each country should decide in advance which groups will have first call on scarce supplies. When establishing goals and setting priorities, policy-makers need to keep in mind the several years needed to construct new production facilities and significantly increase production capacity. Budgetary constraints may extend the time required to stockpile an adequate supply of antivirals to several years. Setting goals related to influenza pandemic preparedness will provide some of the data and incentives needed to increase production or to plan stockpiles. The need for setting goals and establishing priorities extends beyond the borders of any individual country. Estimates of global demand for vaccines and antivirals depend on national estimates fixed in line with the priorities set by individual countries. Priority setting at the national level is thus the first step towards global preparedness for a global event.

Setting goals and priorities for a pandemic is a process that will provide significant health benefits every year. A pandemic influenza planning process will identify problems with the current supply, distribution and use of vaccines and antivirals. Implementing plans to reduce the magnitude of these problems will enhance the availability of vaccines and antivirals for inter-pandemic periods.

Investment in pandemic preparedness thus brings an annual return. Setting goals in a formal, rational, measured process also demonstrates the competence and forward-thinking of leaders and policymakers as custodians of public health.

–  –  –

The following section provides guidelines and recommendations for national health authorities and policy-makers on the process of setting goals and prioritizing the use of available vaccines and antivirals.

3.1 Establishing goals and priorities Setting goals and choosing priorities will require the consideration of logistic, ethical, moral, cultural, legal, and other issues that surround decisions to allocate scarce resources. It is therefore essential that national health authorities work in close collaboration with other public and private sector groups that have roles and interests in protecting public health.

Countries should consider establishing a technical advisory committee with broad representation. The committee should advise policy-makers on goals and priorities, and on ways to improve the supply of vaccines and antivirals2.

The technical committee should first list all goals that should ideally be achieved with available

resources. Examples include:

–  –  –

· limiting economic losses It is useful to explicitly state the units for measuring success. For example, the goal of reducing morbidity could be stated as ‘reduction in morbidity as measured by years of healthy life lost’ or ‘disability-adjusted life-years lost.’ When setting goals, it may also be useful to identify population subsets, such as medical personnel, emergency responders, and leaders, who require priority protection because of their roles during the pandemic response. Definition of these subsets should be flexible, allowing for changes in critical personnel based on likely exposure scenarios. However, when identifying such subsets, it is important to think through the potential practical (financial, political, ethical and health) consequences. For example, if a group is targeted to receive priority prophylaxis or treatment, will their family members also be given first priority? When setting goals, measures considered equitable and essential for each country need to be discussed.

As supplies of vaccines and antivirals are likely to be scarce, meeting all goals simultaneously will be difficult. Planners and policy-makers should therefore prioritize goals. This will facilitate the distribution of supplies in an optimal manner. The strategy for meeting priority goals will also be heavily influenced as the pandemic unfolds and its epidemiology, in terms of who falls ill and who dies, becomes apparent.

In order to define and prioritize goals, advisors and policy-makers will need estimates of the impact of a pandemic, including the number of persons who may become ill (by age and risk group) and the societal and economic consequences of their illness (medical resources used for treatments, costs of treatments, losses in productivity and social functions). Such estimates of impact are important for

–  –  –

allocating resources for planning and responding to a pandemic. Thus there is a need to collect data from which estimates to can be made, for example, the average cost of a case of influenza (including value of lost productivity) and the cost of distributing and administering vaccines and antivirals. To fully appreciate the limitations of current supply, policy-makers also need to know who currently gets vaccines and how they receive them.



Pages:   || 2 | 3 | 4 | 5 |   ...   | 10 |


Similar works:

«Community Champion Network Meeting Thursday 10th July 2014 Attendees John Black (JB) Breathe Easy group Brian Clark (BC) North Southport Individual Locality Representative Lionel Johnson (LJ) Central Southport Individual Locality Representative Ken Lowe (KL) Ainsdale/Birkdale Individual Locality Representative Denise Grant (DG) Southport Community Service Station Carole Holt (CH) Parenting 2000 Louise Malone (LM) Healthy Sefton Gill Mason (GM) The Independent Social Work Partnership Liz Brooks...»

«Filed electronically on 6/27/16 via http://www.regulations.gov June 27, 2016 Mr. Andy Slavitt, Acting Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-5517-P Mail Stop C4-26-05 7500 Security Boulevard Baltimore, MD 21244-1850 Re: Medicare Program; Merit-Based Incentive Payment System (MIPS) and Alternative Payment Model (APM) Incentive Under the Physician Fee Schedule, and Criteria for PhysicianFocused Payment Models – CMS-5517-P...»

«FINAL SUBMISSION REPORT OF EXTRA MURAL RESEARCH PROJECT TITLED: Standardization and clinical evaluation of Keshanjana -an Ayurvedic formulation in Shushkakshipaka (Dry Eye Syndrome) Principal Investigator: Prof. (Dr.) K. S. Dhiman Professor & Head Institute: Department of Shalakya Tantra Institute for Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar, Gujarat-361008 Supported by: Central Council for Research in Ayurvedic Sciences Department of AYUSH, Ministry...»

«1 EYE HEALTH NEEDS ASSESSMENT WALSALL Although the information in this document is from sources believed to be reliable, no warranty express or implied is made or assumed regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any such information, and any and all such warranties are expressly disclaimed. This disclaimer applies to both isolated and aggregate uses of the information. The author furthermore disclaims liability for any loss or damage which may arise as...»

«Package leaflet: Information for the user Risperdal 0.5, 1, 2, 3, 4 and 6 mg film-coated tablets Risperdal Quicklet : 0.5, 1, 2, 3 and 4 mg orodispersible tablets Risperidone Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.• Keep this leaflet. You may need to read it again.• If you have any further questions, ask your doctor or pharmacist.• This medicine has been prescribed for you only. Do not pass it on to...»

«User Manual Invacare SOLO2™ Transportable Oxygen Concentrator Model TPO100 Model TPO100B Dealer: This manual MUST be given to the end user. 0120 User: BEFORE using this product, read this manual and save for future reference. For more information regarding Invacare products, parts, and services, please visit www.invacare.com WARNING DO NOT USE THIS PRODUCT OR ANY AVAILABLE OPTIONAL EQUIPMENT WITHOUT FIRST COMPLETELY READING AND UNDERSTANDING THESE INSTRUCTIONS AND ANY ADDITIONAL INSTRUCTIONAL...»

«ERS TASK FORCE European Respiratory Society Guidelines for the diagnosis and management of lymphangioleiomyomatosis (LAM) S.R. Johnson1, J.F. Cordier2, R. Lazor3,2, V. Cottin2, U. Costabel4, S. Harari5, M. ReynaudGaubert6, A. Boehler7, M. Brauner8, H. Popper9, F. Bonetti10, C. Kingswood11, and the Review panel of the ERS LAM Task Force 1. SR. Johnson, Division of Therapeutics and Molecular Medicine, University of Nottingham, Queens Medical Centre, Nottingham, United Kingdom 2. J.F. Cordier, V....»

«Child's General Anaesthetic:Child Protection Parents 27/10/2008 12:44 Page 16 Your child’s general anaesthetic for dental treatment Causeway Hospital Child's General Anaesthetic:Child Protection Parents 27/10/2008 12:44 Page 1 Contents • Information about general anaesthesia. 3 • Advice before attending for the general 5 anaesthesia appointment.• What happens during the general 9 anaesthetic appointment. a) When you arrive, 9 b) In theatre, 10 c) Recovery. 12 • What to expect after...»

«ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 150 mg of irbesartan and 12.5 mg of hydrochlorothiazide. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. Light pink to pink, film-coated capsule shaped tablet. One side of the tablet debossed with the number 93. The other side...»

«Signifying Authenticity: how valid is a portfolio approach to assessment? Dr Claire Stocks (claire.stocks@learning.ox.ac.uk) Dr Chris Trevitt (chris.trevitt@learning.ox.ac.uk) Oxford Learning Institute, University of Oxford Abstract Portfolios are an increasingly common form of assessment, particularly in education (van der Schaaf and Stokking, 2008; Baume and Yorke, 2002; Mclean and Bullard, 2000) but also in professional courses like medicine and law (eg Driessen and van der Vleuten 2000;...»

«16 Chronic Periaortitis as a Systemic Autoimmune Disease Chang-Hee Suh Rheumatology, Ajou University School of Medicine Korea 1. Introduction Chronic periaortitis is an idiopathic disease whose hallmark is the presence of a fibroinflammatory tissue arising from the adventitia of the abdominal aorta and the common iliac arteries and extending into the surrounding retroperitoneum and frequently encasing neighboring structures such as the ureters and the inferior vena cava (Mitchinson, 1984;...»

«Package leaflet: Information for the user TREVICTA 175 mg prolonged release suspension for injection TREVICTA 263 mg prolonged release suspension for injection TREVICTA 350 mg prolonged release suspension for injection TREVICTA 525 mg prolonged release suspension for injection Paliperidone Read all of this leaflet carefully before you start using this medicine because it contains important information for you.Keep this leaflet. You may need to read it again.If you have any further questions,...»





 
<<  HOME   |    CONTACTS
2016 www.dissertation.xlibx.info - Dissertations, online materials

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.